Verastem, Inc. (VSTM): Price and Financial Metrics

Verastem, Inc. (VSTM): $3.16

0.09 (-2.77%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add VSTM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#181 of 347

in industry

VSTM Price/Volume Stats

Current price $3.16 52-week high $14.22
Prev. close $3.25 52-week low $3.11
Day low $3.11 Volume 383,100
Day high $3.29 Avg. volume 431,204
50-day MA $8.23 Dividend yield N/A
200-day MA $9.16 Market Cap 80.03M

VSTM Stock Price Chart Interactive Chart >


Verastem, Inc. (VSTM) Company Bio


Verastem, Inc. focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. The company was founded in 2010 and is based in Needham, Massachusetts.


VSTM Latest News Stream


Event/Time News Detail
Loading, please wait...

VSTM Latest Social Stream


Loading social stream, please wait...

View Full VSTM Social Stream

Latest VSTM News From Around the Web

Below are the latest news stories about VERASTEM INC that investors may wish to consider to help them evaluate VSTM as an investment opportunity.

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

BOSTON, December 18, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program of its discovery and development collaboration with GenFleet Therapeutics ("GenFleet").

Yahoo | December 18, 2023

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth

As horror film fans know, there’s safety in numbers but robust profitability may be more closer to the domain of uncommon stocks to buy for growth.

Josh Enomoto on InvestorPlace | December 13, 2023

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

BOSTON, December 13, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG-3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the treatment of recurrent low-grade serous ovarian cancer (LGSOC).

Yahoo | December 13, 2023

Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential

If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside.

Josh Enomoto on InvestorPlace | December 3, 2023

3 Penny Stocks to Buy to Turn $1 into $100: November 2023

Are you looking for outsized gains for your portfolio.

Gabriel Osorio-Mazzilli on InvestorPlace | November 22, 2023

Read More 'VSTM' Stories Here

VSTM Price Returns

1-mo -23.30%
3-mo -72.59%
6-mo -60.70%
1-year -63.97%
3-year -94.06%
5-year -84.69%
YTD -61.18%
2023 68.53%
2022 -80.37%
2021 -3.76%
2020 58.96%
2019 -60.12%

Continue Researching VSTM

Here are a few links from around the web to help you further your research on Verastem Inc's stock as an investment opportunity:

Verastem Inc (VSTM) Stock Price | Nasdaq
Verastem Inc (VSTM) Stock Quote, History and News - Yahoo Finance
Verastem Inc (VSTM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!